Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys

Drug Metabolism and Disposition

Volumn 25, Issue 7, 1997, Pages 814-827

  Chang, Mayland ^a   Sood, Virendra K ^b   Kloosterman, David A ^b   Hauer, Michael J ^b   Fagerness, Paul E ^b   Sanders, Phillip E ^b   James Vrbanac, J ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; U 102466; U 88703; U 96183; U 96364; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BIOTRANSFORMATION; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-HIV AGENTS; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAVIRDINE; FEMALE; HIV-1; HYDROLYSIS; INDOLES; MACACA FASCICULARIS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; PIPERAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA FASCICULARIS;

EID: 0030755512     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. T. J. Dueweke, S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley: U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37, 1127-1131 (1993).
2. D. L. Romero, R. A. Morge, M. J. Genin, C. Biles, M. Busso, L. Resnick, I. W. Althaus, F. Reusser, R. C. Thomas, and W. G. Tarpley. Bis(heteroaryl)piperazine (BHAP): reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]- pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 36, 1505-1508 (1993).
3. Y. N. Vaishnav and F. Wong-Staal: The biochemistry of AIDS. Annu. Rev. Biochem. 60, 577-630 (1991).
4. H. Mitsuya, R. Yarchoan, and S. Broder: Molecular targets for AIDS therapy. Science (Washington, DC) 249, 1533-1544 (1990).
5. E. De Clercq: Targets and strategies for the antiviral chemotherapy of AIDS. Trends Pharmacol. Sci. 11, 198-205 (1990).
6. M. A. Fischl, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. King., and The AZT Collaborative Working Group: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 185-191 (1987).
7. R. Yarchoan, H. Mitsuya, C. E. Myers, and S. Broder: Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321, 726-738 (1989).
8. R. Yarchoan, H. Mitsuya, R. V. Thomas, J. M. Pluda, N. R. Hartman, C.-F. Perno, K. S. Marczyk, J. P. Allain, D. G. Johns, and S. Broder: In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science (Washington, DC) 245, 412-417 (1989).
9. J. S. Lambert, M. Seidlin, R. C. Reichman, C. S. Plank, M. Laverty, G. D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F. T. Valentine, and R. Dolin: 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N. Engl. J. Med. 322, 1333-1340 (1990).
10. T. P. Cooley, L. M. Kunches, C. A. Saunders, J. K. Ritter, C. J. Perkins, C. McLaren, R. P. McCaffrey, and H. A. Liebman: Once-daily administration of 2′, 3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a phase I trial. N. Engl. J. Med. 322, 1340-1345 (1990).
11. R. Yarchoan, R. V. Thomas, J.-P. Allain, N. McAtee, R. Dubinsky, H. Mitsuya, T. J. Lawley, B. Safai, C. E. Myers, C. F. Perno, R. W. Klecker, R. J. Wills, M. A. Fischl, M. C. McNeely, J. M. Pluda, M. Leuther, J. M. Collins, and S. Broder: Phase I studies of 2′-3′dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1, 76-81 (1988).
12. S. A. Riddler, R. E. Anderson, and J. W. Mellors: Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, d4T). Antiviral Res. 27, 189-203 (1995).
13. J. A. V. Coates, N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36, 733-739 (1992).
14. H. Soudeyns, X.-J. Yao, Q. Gao, B. Belleau, J.-L. Kraus, N. Nguyen-ba, B. Spira, and M. A. Wainberg: Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocylic nucleoside analog. Antimicrob. Agents Chemother. 35, 1386-1390 (1991).
15. H. König, E. Behr, J. Löwer, and R. Kurth: Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type I reverse transcriptase and DNA polymerase gamma. Antimicrob. Agents Chemother. 33, 2109-2114 (1989).
16. D. D. Richman, M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch, G. G. Jackson, D. T. Durack, S. Nusinoff-Lehrman., and The AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 192-197 (1987).
17. 1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun. 113, 967-974 (1983).
18. U. Piantini, O. W. Sorensen, and R. R. Ernst: Multiple quantum filters for elucidating NMR coupling networks. J. Am. Chem. Soc. 104, 6800-6801 (1982).
19. A. Bax and D. G. Davis: Practical aspects of two-dimensional transverse NOE spectroscopy. J. Magn. Reson. 63, 207-213 (1985).
20. A. Bax and D. G. Davis: MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 65, 355-360 (1985).
21. A. Bax, R. H. Griffey, and B. L. Hawkins: Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR. J. Magn. Reson. 55, 301-315 (1983).
22. A. J. Shaka, P. B. Barker, and R. Freeman: Computer-optimized decoupling scheme for wideband applications and low-level operation. J. Magn. Reson. 64, 547-552 (1985).
23. A. F. Poile and R. D. Conlon: Numerical spectroscopy: absorbance index technique and algorithm for qualitative analysis in liquid chromatography. J. Chromagraphy 204, 149-152 (1981).
24. M. Chang, V. K. Sood, G. J. Wilson, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, and P. E. Fagerness: Metabolism of the reverse transcriptase inhibitor delavirdine in rats. Drug Metab. Dispos. 25, 228-242 (1997).
25. F. W. McLafferty. Interpretation of Mass Spectra (N.J. Turro, ed.), p. 33. University Science Books, Mill Valley, CA, 1980.
26. V. K. Sood, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, J. J. Vrbanac, and M. Chang: Metabolism of the reverse transcriptase inhibitor delavirdine: identification of novel N-acetylglucosamine and pyridinol sulfate conjugates. Presented at "Fourth International Meeting of the International Society for the Study of Xenobiotics," Seattle (Abstract 137), August 27-31, 1995.
27. H-U. Marschall, H. Matern, H. Wietholtz, B. Egestad, S. Matern, and J. Sjövall. Bile acid N-acetylglucosaminidation: in vivo and in vitro evidence for a selective conjugation reaction of 7β-hydroxylated bile acids in man. J Clin. Invest. 89, 1981-1987 (1992).
28. H-U. Marschall, W. J. Griffiths, J. Zhang, H. Wietholtz, H. Matern, S. Matern, and J. Sjövall: Positions of conjugation of bile acids with glucose and N-acetylglucosamine in vitro. J. Lipid Res. 35, 1599-1610 (1994).
29. H-U. Marschall, W. J. Griffiths, U. Götze, J. Zhang, H. Wietholtz, N. Busch, J. Sjövall, and S. Matern: The major metabolites of ursodeoxycholic acid in human urine are conjugated with. N-acetylglucosamine. Hepatology 20, 845-853 (1994).
30. G. L. Skiles and J. D. Adams Jr., and G. S. Yost: Isolation and identification of 3-hydroxy-3-methyloxindole, the major urinary metabolite of 3-methylindole. Chem. Res. Toxicol. 2, 254-259 (1989).
31. V. Fisher, J.-P. Baldeck, and F. L. S. Tse: Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab. Dispos. 20, 603-607 (1992).
32. Y. Tanimoto, H. Kaneko, T. Ohkuma, K. Oguri, and H. Yoshimura: Site-selective oxidation of strychnine by phenobarbital inducible cytrochrome P-450. J. Pharmacobio. Dyn. 14, 161-169 (1991).
33. M. Fujimaki and H. Hakusui: Identification of two major biliary metabolites of carvedilol in rats. Xenobiotica 20, 1025-1034 (1990).
34. O. Beck, B. Jernström, M. Martinez, and D. B. Repke: In vitro study of the aromatic hydroxylation of 1-methyltetrahydro-β-carboline (methtryptoline) in rat. Chem. Biol. Interact. 65, 97-106 (1988).
35. W. H. Schaefer, A. Goalwin, F. Dixon, B. Hwang, L. Killmer, and G. Kuo: Structural determination of glucuronide conjugates and a carbamoyl glucuronide conjugate of carvedilol: Use of acetylation reactions as an aid to determine positions of glucuronidation. Biol. Mass Spectrom. 21, 179-188 (1992).